**Table s10.** GRADE Evidence Profile of Test Accuracy Results for Prevalence/Pre-Test Probability of 40% and 80% for URT vs LRT Sampling (7 studies)

|             | Upper respiratory tract sample | Lower respiratory tract sampling |
|-------------|--------------------------------|----------------------------------|
| Sensitivity | 0.57 (95% CI: 0.42 to 0.71)    | 0.81 (95% CI: 0.73 to 0.86)      |
| Specificity | 1.00 (95% CI: 0.99 to 1.00)    | 1.00 (95% CI: 0.99 to 1.00)      |

| Outcome   | № of<br>studies<br>(№ of<br>patients) | Study<br>design   | Factors that may decrease certainty of evidence |                      |                      | Effect per 1,000 patients tested |  |                             |                               |                                      |                     |                  |
|---|---------------------------------------|---|---|----------------------|----------------------|----------------------------------|--|-----------------------------|-------------------------------|--------------------------------------|---------------------|------------------|
|   |                                       |   | ractors that may decrease certainty of evidence |                      |                      |                                  | pre-test probability of 40% <sup>g</sup> |                             | pre-test probability of 80% h |                                      | Test accuracy CoE   |                  |
|   |                                       |   | Risk of bias                                    | Indirectness         | Inconsistency        | Imprecision                      | Publication bias                         | URT sampling                | LRT<br>sampling               | URT<br>sampling                      | LRT<br>sampling     |                  |
| True positives<br>(patients with<br>COVID-19)                                     | 7 studies<br>1244<br>patients         | cohort & case-control type studies                        | serious <sup>a,b</sup> serious                  |                      | serious <sup>d</sup> | serious <sup>e</sup>             | none                                     | 228 (168 to<br>284)         | 324 (292 to<br>344)           | 456 (336 to<br>568)                  | 648 (584 to<br>688) |                  |
|   |                                       |   |   | serious <sup>c</sup> |                      |                                  |  | 96 fewer TP in URT sampling |                               | 192 fewer TP i <b>n</b> URT sampling |                     | <b>6000</b>      |
| False negatives<br>(patients incorrectly<br>classified as not<br>having COVID-19) |                                       |   |   |                      |                      |                                  |  | 172 (116 to 232)            | 76 (56 to<br>108)             | 344 (232 to<br>464)                  | 152 (112 to<br>216) | VERY LOW         |
|   |                                       |   |   |                      |                      |                                  |  | 96 more FN in URT sampling  |                               | 192 more FN in URT sampling          |                     |                  |
| True negatives<br>(patients without<br>COVID-19)                                  | 1 study<br>8 patients                 | cross-<br>sectional<br>(cohort type<br>accuracy<br>study) | not serious serious °                           |                      | not serious          | very serious <sup>f</sup>        | none                                     | 600 (594 to<br>600)         | 600 (594 to<br>600)           | 200 (198 to<br>200)                  | 200 (198 to<br>200) |                  |
|   |                                       |   |   | serious <sup>c</sup> |                      |                                  |  | 0 fewer TN in URT sampling  |                               | 0 fewer TN in URT sampling           |                     | ⊕○○○<br>VERY LOW |
| False positives (patients incorrectly   |                                       |   |   |                      |                      |                                  |  | 0 (0 to 6)                  | 0 (0 to 6)                    | 0 (0 to 2)                           | 0 (0 to 2)          |                  |

## IDSA Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing

## Supplementary Materials

| classified as having COVID-19) | 0 fewer FP in URT 0 fewer FP in URT sampling sampling |  |
|--------------------------------|---|--|
|--------------------------------|---|--|

**Explanations:** This table is based on applying the sensitivity and specificity estimates to calculate True and false positives and negatives in a hypothetical population of 1000 individuals

- a. The case-control design leads to a serious study population bias.
- b. The Fengting Y. (2020) study showed results as the number of samples and not the number of patients.
- c. There was no direct evidence comparing the accuracy of a strategy with starting with upper sample and then conducting a lower sample if the upper sample is negative. Additionally, studies reported test accuracy results but did not report on patient-important and population-important outcomes based on the results.
- d. There is serious unexplained heterogeneity.
- e. Considering the upper vs lower limits of the sensitivity's confidence interval would lead to different clinical decisions.
- f. A very low number of patients.
- g. Typically seen in patients meeting clinical definition for COVID-19 who were hospitalized.
- h. Typically seen in patients meeting clinical definition for COVID-19 who were admitted to intensive care units.